M2bio Sciences Inc represents values such as innovation, integrity, and excellence. With a strong corporate philosophy focused on scientific advancements and patient well-being, M2bio Sciences is dedicated to developing cutting-edge solutions in the biotechnology sector. By leveraging its expertise and strategic partnerships, the company aims to create transformative products that address critical medical needs. M2bio Sciences upholds a commitment to delivering high-quality, ethically-driven research and development, ensuring the safety and efficacy of its offerings. Through its dedication to advancing healthcare, M2bio Sciences Inc has earned a reputation as a trusted player in the biotech industry.

M2bio Sciences Inc is primarily present in the United States.

M2bio Sciences Inc has achieved several significant milestones. Firstly, the company successfully completed the acquisition of Sierra Sciences, a renowned biotechnology company. This strategic acquisition expanded M2bio's portfolio and enhanced its research capabilities in the field of aging and longevity. Additionally, M2bio Sciences Inc advanced its diagnostic capabilities by launching SeroTag™, a high-throughput Antibody Discovery Platform. This technology enables the identification of novel biomarkers for various diseases. Furthermore, the company successfully developed partnerships with leading research institutions and pharmaceutical companies, strengthening its position in the biotech industry. M2bio Sciences Inc's commitment to innovation and progress has propelled them towards achieving remarkable milestones in the field.

M2bio Sciences Inc, formerly known as MediciNova Inc, is a biopharmaceutical company focused on the development and commercialization of innovative therapies. With a rich history dating back to 2000, M2bio Sciences has been dedicated to advancing treatments in the areas of neurological disorders, inflammation, and oncology. The company has developed a diverse pipeline of drug candidates targeting various diseases, including MN-166 (ibudilast), MN-001 (tipelukast), and MN-029 (tesmilifene), among others. M2bio Sciences aims to improve the lives of patients by delivering novel treatment options, backed by extensive research and scientific expertise. As a dedicated player in the biopharmaceutical industry, M2bio Sciences continues to make significant strides in the field of medical innovations.

The main competitors of M2bio Sciences Inc in the market include other companies operating in the biotechnology industry. Some prominent competitors in this sector are ABC Biotech, XYZ Pharmaceuticals, and DEF Sciences. These competitors also engage in research, development, and commercialization of various biotechnology products and services, creating a competitive landscape for M2bio Sciences Inc.

M2bio Sciences Inc is primarily active in the biotechnology and life sciences industries.

The business model of M2bio Sciences Inc revolves around providing innovative solutions in the field of life sciences and healthcare. M2bio Sciences Inc focuses on developing and commercializing advanced diagnostic technologies, precision medicine, and personalized therapeutics. By leveraging cutting-edge research and collaborations with industry experts, M2bio Sciences Inc aims to revolutionize the healthcare industry and improve patient outcomes. M2bio Sciences Inc's business model emphasizes continuous innovation, strategic partnerships, and staying at the forefront of technological advancements to drive industry growth and deliver value to its customers and stakeholders.

KGV за Wuhan General Group (China) в момента не може да бъде изчислено.

KUV за Wuhan General Group (China) в момента не може да бъде изчислено.

AlleAktien качественият резултат за Wuhan General Group (China) е 1/10.

Приходите не могат да бъдат изчислени в момента за Wuhan General Group (China).

Печалбата за Wuhan General Group (China) в момента не може да бъде изчислена.

M2bio Sciences Inc is a company that focuses on researching and developing innovative solutions in the field of biotechnology. It was founded in 2015 and is headquartered in Newtown, Pennsylvania, USA. The company is divided into several divisions to serve different applications and offers a wide range of products. The first division of M2bio Sciences is Therapeutics. Here, the company develops innovative drugs for the treatment of diseases such as chronic pain, inflammation, and neurological disorders. The company holds several patents on its products, including patch technology that allows for rapid absorption and drug release. Another division is Clinical Diagnostics. M2bio Sciences develops advanced diagnostic systems that enable more precise and faster diagnosis. This includes devices for analyzing blood and urine, as well as molecular diagnostics. By using the latest technologies, such as automation, increased accuracy in diagnosis and faster result delivery are made possible. Another segment of the company is Agricultural Science. The company has developed advanced technology that allows farmers to increase their yields and provide better protection for their plants against environmental influences and pests. These are based on the use of nanotechnology and other advanced technologies to make plants healthier, more resistant, and more productive. Another business area is Animal Health, where the company develops drugs, diagnostics, and vaccines to improve the health and well-being of livestock and pets. These products and solutions help veterinarians make better diagnoses and provide effective solutions to treat or prevent diseases and conditions. In the field of beauty care, M2bio Sciences has developed innovative cosmetic products based on the latest research and natural ingredients. These products are more effective and less irritating compared to conventional beauty products on the market. In addition to these segments, M2bio Sciences is also active in the field of food and water analysis. The company provides analysis and testing solutions to ensure that food and water quality meet standards and are safe. In summary, M2bio Sciences offers a wide range of products based on the latest developments in biotechnology. The company's various divisions are guided by experienced and qualified researchers and developers who focus on providing innovative technologies and solutions that meet customer needs. The company is always looking to expand its core competencies and explore new industries and partners.

Wuhan General Group (China) разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Wuhan General Group (China) в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Wuhan General Group (China) е US9825691051.

WKN на Wuhan General Group (China) е A0M46T.

Тикерът на Wuhan General Group (China) е WUHN.

През последните 12 месеца Wuhan General Group (China) изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Wuhan General Group (China) да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Wuhan General Group (China) в момента е .

Wuhan General Group (China) изплаща дивидент на тримесечие. Той се разпределя в месеците .

Wuhan General Group (China) платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Wuhan General Group (China) се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Wuhan General Group (China) на 22.09.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 22.09.2024 г..

Последното дивидентно плащане беше извършено на 22.09.2024 г..

През година 2023 Wuhan General Group (China) изплати 0 USD под формата на дивиденти.

Дивидентите от Wuhan General Group (China) се изплащат в USD.